FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours ner resnonse.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ma Songjiang					2. Issuer Name and Ticker or Trading Symbol GYRE THERAPEUTICS, INC. [ GYRE ]						(Ch	Directo	cable) or	Person(s) to Iss	vner		
(Last)	`	irst) PEUTICS, INC.	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/14/2024							Officer (give title Other (specify below)  President				
12770 HIGH BLUFF DRIVE, SUITE 150				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN DIE	EGO C.	A	92130										-	led by More	Reporting Perso		
(City)	(S	tate)	(Zip)		R	Rule 10b5-1(c) Transaction Indication											
Check this box to indicate that a transaction was made pursuant to a contract, in satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										act, instructio n 10.	n or written pla	n that is intende	d to				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,		Code (Instr. 5)					s Fally (I	orm: Direct	7. Nature of Indirect Beneficial Ownership			
									Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Ye	Date,	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$9.98	08/14/2024			A		26,000		(1)	08/14/2034	Common Stock	26,000	\$0	26,000	D		

## Explanation of Responses:

1. This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date.

/s/ Ruoyu Chen, as attorney-infact for Songjiang Ma

08/16/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.